Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 730-743
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.730
MicroRNAs in cancer therapeutic response: Friend and foe
Jingyan Xue, Jixiao Niu, Jiong Wu, Zhao-Hui Wu
Jingyan Xue, Jiong Wu, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Jingyan Xue, Jiong Wu, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Jixiao Niu, Zhao-Hui Wu, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States
Jingyan Xue, Jixiao Niu, Zhao-Hui Wu, Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, United States
Author contributions: Xue J and Niu J were involved in writing the manuscript; all authors discussed the content and revised the manuscript.
Correspondence to: Jingyan Xue, MD, Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China. jxue7@uthsc.edu
Telephone: +1-901-4482155 Fax: +1-901-4483910
Received: January 5, 2014
Revised: June 7, 2014
Accepted: June 18, 2014
Published online: October 10, 2014
Core Tip

Core tip: MicroRNAs (miRNAs) have been shown to play critical roles in cancer pathogenesis and progression by modulating tumor initiation, growth, metastasis, and therapeutic resistance. In this review, we discuss the recent progress in understanding miRNA function in cancer development and therapeutic response, especially in breast cancer, as well as the potential application of using miRNA signatures as biomarkers for predicting therapeutic response and for personalizing anti-cancer regimens.